Publications by authors named "Ginger D Constantine"

Claim this Profile
1
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Andrew M Kaunitz, Diana Bitner, Ginger D Constantine, Brian Bernick, Shelli Graham

Menopause· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Ginger D Constantine, James A Simon, Andrew M Kaunitz, James H Pickar, Dennis A Revicki

Menopause· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic estradiol levels with low-dose vaginal estrogens.
Richard J Santen, Sebastian Mirkin, Brian Bernick, Ginger D Constantine

Menopause· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep.
Herman Weiss, Bridget Martell, Ginger D Constantine, Sarah M Davis, Justin D Vidal

Drug Deliv Transl Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in Sheep.
Herman Weiss, Bridget Martell, Ginger D Constantine, Sarah M Davis, Justin D Vidal

J Pharm Sci· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Rogerio A Lobo, James Liu, Frank Z Stanczyk, Ginger D Constantine, James H Pickar

Menopause· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review.
Ginger D Constantine, Shelli Graham, Kate Lapane, Kathleen Ohleth, Brian Bernick

Menopause· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Ginger D Constantine, Dennis A Revicki, Risa Kagan, James A Simon, Shelli Graham

Menopause· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.
Ginger D Constantine, Grant Kessler, Shelli Graham, Steven R Goldstein

J Womens Health (Larchmt)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Sebastian Mirkin, Shelli Graham, Dennis A Revicki, Randall H Bender, Brian Bernick, Ginger D Constantine

Menopause· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
Ginger D Constantine, James A Simon, James H Pickar, David F Archer, Brian Bernick

Curr Med Res Opin· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To the Editor.
David F Archer, James H Pickar, Ginger D Constantine, Annette M Shadiack, Brian Bernick

Menopause· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Rogerio A Lobo, David F Archer, Risa Kagan, Andrew M Kaunitz, Ginger D Constantine

Obstet Gynecol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
James A Simon, David F Archer, Risa Kagan, Brian Bernick, Shelli Graham, Ginger D Constantine

Menopause· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.
Sheryl A Kingsberg, Robin Kroll, Irwin Goldstein, Harvey Kushner, Brian Bernick, Ginger D Constantine

Menopause· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Reply.
David F Archer, Ginger D Constantine, James Simon, Harvey Kushner, Philip Mayer

Menopause· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
Ginger D Constantine, Celine Bouchard, James H Pickar, David F Archer, Shelli Graham

J Womens Health (Larchmt)· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol.
David F Archer, Ginger D Constantine, James A Simon, Harvey Kushner, Philip Mayer

Menopause· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
James A Simon, David F Archer, Ginger D Constantine, James H Pickar, Julia M Amadio

Maturitas· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Ginger D Constantine, James A Simon, James H Pickar, David F Archer, Harvey Kushner

Menopause· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
Gary Hattersley, Alan G Harris, James A Simon, Ginger D Constantine

Menopause· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Sheryl A Kingsberg, Leonard Derogatis, James A Simon, Ginger D Constantine, Shelli Graham

J Sex Med· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and Rebuttal to Editorial Comment on TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women with Vulvar and Vaginal Atrophy: The REJOICE Trial.
Sheryl A Kingsberg, Leonard Derogatis, James A Simon, Ginger D Constantine, Shelli Graham

J Sex Med· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribing of FDA-approved and compounded hormone therapy differs by specialty.
Ginger D Constantine, David F Archer, Shelli Graham, Brian A Bernick, Sebastian Mirkin

Menopause· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.
Ginger D Constantine, David F Archer, Ricki Pollycove, Wei Jiang, Corrado Altomare

Menopause· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis